Caption Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Caption Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$157K	–	1491
2022 Q4	$157K	Buy	+50,000	New	+$194K	﹤0.01%	1092
2022 Q3	–	Sell	-50,000	Closed	-$207K	–	1811
2022 Q2	$207K	Hold	50,000	–	–	﹤0.01%	1230
2022 Q1	$291K	Sell	50,000 -10,000	-17%	-$59.5K	﹤0.01%	1221
2021 Q4	$452K	Hold	60,000	–	–	0.01%	1276
2021 Q3	$541K	Hold	60,000	–	–	0.01%	1188
2021 Q2	$716K	Sell	60,000 -40,000	-40%	-$453K	0.01%	972
2021 Q1	$1.25M	Buy	100,000 +65,000	+186%	+$876K	0.03%	636
2020 Q4	$546K	Buy	+35,000	New	+$410K	0.01%	724
2020 Q3	–	Sell	-40,000	Closed	-$358K	–	1231
2020 Q2	$358K	Hold	40,000	–	–	0.01%	732
2020 Q1	$255K	Buy	40,000 +25,000	+167%	+$186K	0.01%	667
2019 Q4	$125K	Buy	+15,000	New	+$138K	﹤0.01%	746
2019 Q3	–	Sell	-17,500	Closed	-$189K	–	868
2019 Q2	$189K	Buy	+17,500	New	+$186K	0.01%	572

Other funds holding SGMO

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caption Management's SGMO Position: Q2 2025 in Review

Caption Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 55,700 shares — an estimated $36.5K sold.

Caption Management first reported a position in SGMO in Q2 2018 and held it in 11 quarters. The position peaked at $876K in Q2 2018. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

Caption Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
Caption Management sold 55,700 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $36.5K.
Caption Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 11 quarters.
Caption Management's SANGAMO THERAPEUTICS INC position peaked at $876K in Q2 2018.
114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.